Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Incyte (INCY) suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading.Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline.Image Source: Zacks Investment ResearchINCY Pauses Enrollment in CSU StudyIncyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings ...